Clomacran in the treatment of schizophrenic patients: a comparison of two assessment methods

In an uncontrolled clinical trial clomacran, the chlorpromazine analogue of the acridane series, was found to be therapeutically effective in the treatment of newly admitted schizophrenic patients. There was essentially no difference in the sensitivity of the two assessment instruments, i.e. BPRS and PAF, in the detection of therapeutic changes. On the other hand, the PAF, a 123-item scale, was found to be more sensitive for the description of a schizophrenic patient population than the BPRS, an 18-item scale.